S&P 500   3,895.17 (+2.20%)
DOW   31,591.47 (+2.13%)
QQQ   321.28 (+2.27%)
AAPL   125.96 (+3.88%)
MSFT   236.43 (+1.74%)
FB   260.86 (+1.26%)
GOOGL   2,054.12 (+1.59%)
TSLA   711.93 (+5.39%)
AMZN   3,114.24 (+0.69%)
NVDA   548.11 (-0.09%)
BABA   239.87 (+0.89%)
CGC   35.02 (+6.93%)
GE   13.22 (+5.42%)
MU   94.46 (+3.20%)
NIO   49.74 (+8.65%)
AMD   85.28 (+0.91%)
T   28.22 (+1.18%)
F   12.05 (+2.99%)
ACB   11.31 (+7.51%)
DIS   195.10 (+3.21%)
BA   224.42 (+5.85%)
NFLX   550.07 (+2.08%)
BAC   35.63 (+2.65%)
S&P 500   3,895.17 (+2.20%)
DOW   31,591.47 (+2.13%)
QQQ   321.28 (+2.27%)
AAPL   125.96 (+3.88%)
MSFT   236.43 (+1.74%)
FB   260.86 (+1.26%)
GOOGL   2,054.12 (+1.59%)
TSLA   711.93 (+5.39%)
AMZN   3,114.24 (+0.69%)
NVDA   548.11 (-0.09%)
BABA   239.87 (+0.89%)
CGC   35.02 (+6.93%)
GE   13.22 (+5.42%)
MU   94.46 (+3.20%)
NIO   49.74 (+8.65%)
AMD   85.28 (+0.91%)
T   28.22 (+1.18%)
F   12.05 (+2.99%)
ACB   11.31 (+7.51%)
DIS   195.10 (+3.21%)
BA   224.42 (+5.85%)
NFLX   550.07 (+2.08%)
BAC   35.63 (+2.65%)
S&P 500   3,895.17 (+2.20%)
DOW   31,591.47 (+2.13%)
QQQ   321.28 (+2.27%)
AAPL   125.96 (+3.88%)
MSFT   236.43 (+1.74%)
FB   260.86 (+1.26%)
GOOGL   2,054.12 (+1.59%)
TSLA   711.93 (+5.39%)
AMZN   3,114.24 (+0.69%)
NVDA   548.11 (-0.09%)
BABA   239.87 (+0.89%)
CGC   35.02 (+6.93%)
GE   13.22 (+5.42%)
MU   94.46 (+3.20%)
NIO   49.74 (+8.65%)
AMD   85.28 (+0.91%)
T   28.22 (+1.18%)
F   12.05 (+2.99%)
ACB   11.31 (+7.51%)
DIS   195.10 (+3.21%)
BA   224.42 (+5.85%)
NFLX   550.07 (+2.08%)
BAC   35.63 (+2.65%)
S&P 500   3,895.17 (+2.20%)
DOW   31,591.47 (+2.13%)
QQQ   321.28 (+2.27%)
AAPL   125.96 (+3.88%)
MSFT   236.43 (+1.74%)
FB   260.86 (+1.26%)
GOOGL   2,054.12 (+1.59%)
TSLA   711.93 (+5.39%)
AMZN   3,114.24 (+0.69%)
NVDA   548.11 (-0.09%)
BABA   239.87 (+0.89%)
CGC   35.02 (+6.93%)
GE   13.22 (+5.42%)
MU   94.46 (+3.20%)
NIO   49.74 (+8.65%)
AMD   85.28 (+0.91%)
T   28.22 (+1.18%)
F   12.05 (+2.99%)
ACB   11.31 (+7.51%)
DIS   195.10 (+3.21%)
BA   224.42 (+5.85%)
NFLX   550.07 (+2.08%)
BAC   35.63 (+2.65%)
Log in
NASDAQ:CRBP

Corbus Pharmaceuticals Stock Forecast, Price & News

$2.35
+0.17 (+7.80 %)
(As of 03/1/2021 11:25 AM ET)
Add
Compare
Today's Range
$2.24
Now: $2.35
$2.38
50-Day Range
$1.41
MA: $2.30
$3.42
52-Week Range
$0.91
Now: $2.35
$9.78
Volume224,210 shs
Average Volume19.53 million shs
Market Capitalization$197.49 million
P/E RatioN/A
Dividend YieldN/A
Beta2.14
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
Corbus Pharmaceuticals logo

Headlines

CRBP Feb 2021 2.000 call
January 24, 2021 |  uk.finance.yahoo.com
CRBP Feb 2021 1.000 call
January 23, 2021 |  uk.finance.yahoo.com
CRBP Feb 2021 0.500 call
January 23, 2021 |  uk.finance.yahoo.com
CRBP Feb 2021 1.500 call
January 21, 2021 |  uk.finance.yahoo.com
The Little-Known Tech That Could Transform Healthcare
January 19, 2021 |  marketwatch.com
Is CRBP A Good Stock To Buy Now?
December 7, 2020 |  finance.yahoo.com
BB, MRNA, LI and LYG among premarket gainers
December 2, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRBP
CUSIPN/A
Phone617-963-0100
Employees141
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.14 million
Book Value$0.10 per share

Profitability

Net Income$-71,450,000.00
Net Margins-2,208.06%

Miscellaneous

Market Cap$197.49 million
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

219th out of 1,962 stocks

Pharmaceutical Preparations Industry

104th out of 772 stocks

Analyst Opinion: 3.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$2.35
+0.17 (+7.80 %)
(As of 03/1/2021 11:25 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

Is Corbus Pharmaceuticals a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Corbus Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRBP, but not buy additional shares or sell existing shares.
View analyst ratings for Corbus Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Corbus Pharmaceuticals?

Wall Street analysts have given Corbus Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Corbus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Corbus Pharmaceuticals?

Corbus Pharmaceuticals saw a increase in short interest in the month of February. As of February 12th, there was short interest totaling 22,140,000 shares, an increase of 50.7% from the January 28th total of 14,690,000 shares. Based on an average daily trading volume, of 14,360,000 shares, the short-interest ratio is presently 1.5 days.
View Corbus Pharmaceuticals' Short Interest
.

When is Corbus Pharmaceuticals' next earnings date?

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Corbus Pharmaceuticals
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) posted its earnings results on Monday, November, 16th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.42). The biopharmaceutical company had revenue of $1.23 million for the quarter, compared to analyst estimates of $3.42 million. Corbus Pharmaceuticals had a negative net margin of 2,208.06% and a negative trailing twelve-month return on equity of 485.45%.
View Corbus Pharmaceuticals' earnings history
.

How has Corbus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRBP shares have decreased by 44.2% and is now trading at $2.30.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CRBP?

9 equities research analysts have issued 1-year price objectives for Corbus Pharmaceuticals' shares. Their forecasts range from $2.50 to $112.00. On average, they expect Corbus Pharmaceuticals' stock price to reach $26.39 in the next twelve months. This suggests a possible upside of 1,047.3% from the stock's current price.
View analysts' price targets for Corbus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the following people:
  • Dr. Yuval Cohen, CEO & Director (Age 46, Pay $810.55k)
  • Mr. Sean F. Moran CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 63, Pay $520k)
  • Dr. Barbara White, Head of Research & Chief Medical Officer (Age 71, Pay $570.7k)
  • Ted Jenkins, Sr. Director of Investor Relations & Corp. Communications
  • Dr. Mark A. Tepper, Co-Founder & Consultant (Age 64)
  • Scott Constantine, Sr. Director & Head of Clinical Operations
  • Mr. Craig Stuart Millian M.B.A., Chief Commercial Officer (Age 53)
  • Sergei Atamas, Exec. Director of Research

Who are some of Corbus Pharmaceuticals' key competitors?

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), (CGC), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include ETF Managers Group LLC (9.64%), BlackRock Inc. (6.21%), Renaissance Technologies LLC (1.14%), Pinnacle Associates Ltd. (1.12%), Northern Trust Corp (0.99%) and Charles Schwab Investment Management Inc. (0.53%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen.
View institutional ownership trends for Corbus Pharmaceuticals
.

Which major investors are selling Corbus Pharmaceuticals stock?

CRBP stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, BlackRock Inc., Pinnacle Associates Ltd., Wells Fargo & Company MN, Ikarian Capital LLC, Bank of New York Mellon Corp, Alliancebernstein L.P., and Citigroup Inc..
View insider buying and selling activity for Corbus Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Corbus Pharmaceuticals stock?

CRBP stock was bought by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, JPMorgan Chase & Co., Squarepoint Ops LLC, Virtu Financial LLC, Davy Global Fund Management Ltd, Renaissance Technologies LLC, LPL Financial LLC, and Vontobel Holding Ltd.. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, Craig Stuart Millian, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran, and Yuval Cohen.
View insider buying and selling activity for Corbus Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $2.30.

How much money does Corbus Pharmaceuticals make?

Corbus Pharmaceuticals has a market capitalization of $193.29 million and generates $36.14 million in revenue each year. The biopharmaceutical company earns $-71,450,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

How many employees does Corbus Pharmaceuticals have?

Corbus Pharmaceuticals employs 141 workers across the globe.

What is Corbus Pharmaceuticals' official website?

The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

Where are Corbus Pharmaceuticals' headquarters?

Corbus Pharmaceuticals is headquartered at 500 River Ridge Drive, Norwood MA, 02062.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.